The Value of Diagnostic Testing in Personalized Medicine

References

Aspinall, M. G. and R. G. Hamermesh (2007) “Realizing the Promise of Personalized Medicine,” Harvard Business Review, 85(10):108–117.Suche in Google Scholar

Brune, K., H. A. Katus, J. Moecks, E. Spanuth, A. S. Jaffe and E. Giannitsis (2008) “N-Terminal Pro-B-Type Natriuretic Peptide Concentrations Predict the Risk of Cardiovascular Adverse Events from Antiinflammatory Drugs: A Pilot Trial,” Clinical Chemistry, 54(7):1149–1157.10.1373/clinchem.2007.097428Suche in Google Scholar

Carlson, J. J., L. P. Garrison Jr and S. D. Sullivan (2009) “Paying for Outcomes: Innovative Coverage and Reimbursement Schemes for Pharmaceuticals,” Journal of Management Care Pharmacology, 15(8):683.10.18553/jmcp.2009.15.8.683Suche in Google Scholar

Davis, J.C., L. Furstenthal, A. A. Desai, T. Norris, S. Sutaria, E. Fleming and P. Ma (2009) “The Microeconomics of Personalized Medicine: Today’s Challenge and Tomorrow’s Promise,” Natural Review Drug Discovery, 8(4):279–286.10.1038/nrd2825Suche in Google Scholar

Elkin, E. B., M. C. Weinstein, E. P. Winer, K. M. Kuntz, S. J. Schnitt and J. C. Weeks (2004) “HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis,” Journal of Clinical Oncology, 22(5):854–863.10.1200/JCO.2004.04.158Suche in Google Scholar

Epstein, R. S., T. P. Moyer, R. E. Aubert, D. J. Okane, F. Xia, R. R. Verbrugge, B. F. Gage and J. R. Teagarden (2010) “Warfarin Genotyping Reduces Hospitalization Rates Results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study),” Journal of the American College of Cardiology, 55(25):2804–2812.10.1016/j.jacc.2010.03.009Suche in Google Scholar

Faulkner, E. (2009) “Clinical Utility or Impossibility? Addressing the Molecular Diagnostics Assessment and Reimbursement Conundrum,” Journal of Managed Care Medicine, 12(4): 42–.Suche in Google Scholar

Gardiner, S. J. and E. J. Begg (2005) “Pharmacogenetic Testing for Drug Metabolizing Enzymes: Is It Happening in Practice?” Pharmacogenetics and Genomics, 15(5):365.10.1097/01213011-200505000-00013Suche in Google Scholar

Gaughan, E. M. and D. B. Costa (2011) “Genotype-Driven Therapies for Non-Small Cell Lung Cancer: Focus on EGFR, KRAS and ALK Gene Abnormalities,” Therapeutic Advances in Medical Oncology, 3(3):113–125.10.1177/1758834010397569Suche in Google Scholar

Health Advances (2010) “The Reimbursement Landscape for Novel Diagnostics.”Suche in Google Scholar

Hudis, C. A. (2007) “Trastuzumab – Mechanism of Action and Use in Clinical Practice,” New England Journal of Medicine, 357(1):39–51.10.1056/NEJMra043186Suche in Google Scholar

Institute of Medicine (2010) Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary. Washington, DC: The National Academies Press.Suche in Google Scholar

Kemp, L. K., C. M. Doran, T. Vos and W. Hall (2007) “Cost-Effectiveness Analysis of Genetic Screening for the Taq1B Polymorphism in the Secondary Prevention of Coronary Heart Disease,” Expert Review of Pharmacoeconomics and Outcomes Research, 7(2):119–128.10.1586/14737167.7.2.119Suche in Google Scholar

Lakdawalla, D. N., E. C. Sun, A. B. Jena, C. M. Reyes, D. P. Goldman and T. J. Philipson (2010) “An Economic Evaluation of the War on Cancer,” Journal of Health Economics, 29(3):333–346.10.1016/j.jhealeco.2010.02.006Suche in Google Scholar

McCabe, L. L. and E. R. McCabe (2008) “Expanded Newborn Screening: Implications for Genomic Medicine,” Annual Review of Medicine, 59:163–175.10.1146/annurev.med.59.110106.132016Suche in Google Scholar

McGhee, S. A., E. R. Stiehm and E. R. McCabe (2005) “Potential Costs and Benefits of Newborn Screening for Severe Combined Immunodeficiency,” The Journal of Pediatrics, 147(5): 603–608.10.1016/j.jpeds.2005.06.001Suche in Google Scholar

Nelson, P. (1970) “Information and Consumer Behavior,” Journal of Political Economy, 78(2):311–329.10.1086/259630Suche in Google Scholar

Philipson, T. J. and A. B. Jena (2005) “Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs,” NBER Working Paper Series, No. 11810.Suche in Google Scholar

Psaty, B. M. and C. D. Furberg (2005) “COX-2 Inhibitors – Lessons in Drug Safety,” New England Journal of Medicine, 352(11):1133–1135.10.1056/NEJMe058042Suche in Google Scholar

Ruff, C. T., D. A. Morrow, P. Jarolim, F. Ren, C. F. Contant, A. Kaur, S. P. Curtis, L. Laine, C. P. Cannon and K. Brune (2011) “Evaluation of NT-proBNP and High Sensitivity C-Reactive Protein for Predicting Cardiovascular Risk in Patients with Arthritis Taking Longterm Nonsteroidal Antiinflammatory Drugs,” Journal of Rheumatology, 38(6):1071–1078.10.3899/jrheum.100880Suche in Google Scholar

Seabury, S. A., D. P. Goldman, J. R. Maclean, J. R. Penrod and D. N. Lakdawalla (2012) “Patients Value Metastatic Cancer Therapy more Highly than is Typically shown through Traditional Estimates,” Health Affairs, 31(4):691–699.10.1377/hlthaff.2012.0174Suche in Google Scholar

Sood, N., T. Philipson and P. Huckfeldt (2013) “Quantifying the Value of Personalized Medicines: Evidence from COX-2 Inhibitors,” Forum for Health Economics and Policy, 16(1):1–22.10.1515/fhep-2013-0005Suche in Google Scholar

The Lewin Group (2005) The Value of Diagnostics Innovation, Adoption and Diffusion into Health Care, Prepared for the Advanced Medical Technology Association.Suche in Google Scholar

U.S. Food and Drug Administration (2004) Safety of Vioxx: FDA Public Health Advisory. Washington, DC.Suche in Google Scholar

UnitedHealth Group (2012) “Personalized Medicine: Trends and Prospects for the New Science of Genetic Testing and Molecular Diagnostics,” Working Paper 7.Suche in Google Scholar